Is colchicine effective in Peyronie's disease? A pilot study

Area of Science:

• Urology
• Andrology
• Pharmacology

Background:

• Current treatments for Peyronie's disease using oral or topical agents have yielded unsatisfactory outcomes.
• Peyronie's disease is characterized by fibrous plaque formation, leading to penile curvature and erectile dysfunction.

Purpose of the Study:

• To investigate the efficacy of colchicine as a potential treatment for Peyronie's disease.
• To evaluate colchicine's effects on Peyronie's plaque, penile curvature, and associated symptoms.

Main Methods:

• A pilot study involving 24 previously untreated patients diagnosed with Peyronie's disease.
• Oral administration of colchicine for a duration of 3 to 5 months.
• Assessment of changes in Peyronie's plaque, penile curvature, pain, and erectile function.

Main Results:

• Significant reduction or complete resolution of Peyronie's plaque observed in 50% (12/24) of patients.
• Painful erections were relieved in 78% (7/9) of affected patients.
• Improvement in penile curvature noted in 37% (7/19) of cases; no changes in erectile status or penile narrowing.

Conclusions:

• Colchicine demonstrates potential therapeutic benefits in managing Peyronie's disease, particularly plaque reduction and pain relief.
• Further investigation through prospective, double-blind clinical trials is warranted to confirm colchicine's definitive role in treatment.